Articles from: HCP Live
In this interview, Siperstein explained some of the biggest takeaways from her conference presentation on advances in microneedling techniques, including radiofrequency...
ICYMI: In this #AAD23 interview, Dr. Robyn Siperstein explained some of the biggest takeaways from her conference presentation on advances in #microneedling techniques, including radiofrequency specifically: https://t.co/y8nSA7dY21 - view on twitter
A phase 2 trial comparing once weekly basal insulin Fc against once daily insulin degludec, results of the study will help provide the basis...
New research from a phase 2 trial suggests once-weekly basal insulin Fc achieved similar glycemic control as once-daily insulin degludec in patients with #Type2Diabetes: https://t.co/N6YjjcpB4X - view on twitter
Statistical analysis showed no differences between each pairwise comparison of the bevacizumab biosimilars, MB02-SP and MB02-DM, and the reference...
The bevacizumab #biosimilars, MB02-SP (Standard Process) and MB02-DM (Defined Media), demonstrated similar pharmacokinetics (PK), safety, immunogenicity, and bioequivalence compared with the reference drug. https://t.co/vsvvQ9JNzX - view on twitter
Upadacitinib, a selective and reversible Janus kinase (JAK) inhibitor, may be a promising treatment option for patients with systemic lupus...
#Upadacitinib, a selective and reversible Janus kinase (JAK) inhibitor, may be a promising treatment option for patients with systemic #lupus erythematosus: https://t.co/GxKD0cgs0O - view on twitter
Mashup Score:1HCP Live
Industry Payments to Cardiologists Totaled Over $1 Billion From 2014 to 2019 - 17 hours
Industry payments to cardiologists remained highly prevalent in each year of study, but the research showed significant declines in the total value of payments...
Cardiologists in the United States received 5.5 million industry payments totaling $1.1 billion from 2014 to 2019, according to new study results. Read more: https://t.co/mDOQs0peqC #cardiology - view on twitter
Mashup Score:1HCP Live
FDA Approves High-Concentration Formulation Biosimilar Adalimumab-Adaz - 19 hours
The approval was based on positive results from the phase I pharmacokinetics bridging study, which showed comparable PK and similar safety and immunogenicity of...
ICYMI: The FDA approval was based on positive results from the phase I pharmacokinetics bridging study, which showed comparable PK and similar safety and immunogenicity of #biosimilar adalimumab 50 mg/mL and adalimumab high-concentration formulation. https://t.co/UBfYCpBagR - view on twitter
New data highlighted racial and ethnic differences between patients with Merkel cell carcinoma, indicating that rates for survival were roughly similar but other distinctions...
New data highlighted racial & ethnic differences between Merkel cell carcinoma patients, indicating that rates for survival were similar but other distinctions remained. Check out the story here: https://t.co/7la2G7yPKm - view on twitter
In a recent phase 2 trial, abatacept failed to significantly reduce progression to diabetes or abnormal glucose tolerance among a cohort of stage 1...
Abatacept missed the mark for its primary endpoint in a recent phase 2 trial for preventing or delaying #Type1Diabetes: https://t.co/38ZYYm3C3F - view on twitter
No significant budget increase was observed in patients with non-radiographic axial spondyloarthritis (nr-axSpA) receiving...
No significant budget increase was observed in patients with non-radiographic axial spondyloarthritis (nr-axSpA) receiving #secukinumab: https://t.co/IrsJuZjhBV - view on twitter
A new survey found the COVID-19 pandemic changed many Americans view of obesity and caused others to consider new weight-loss methods due to their...
Approximately 6.4 million Americans considered having weight-loss surgery or using anti- #obesity prescription drugs during the #COVID19 pandemic. Read more: https://t.co/FT1dJBkPfs - view on twitter